Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Confident in future growth driven by our strength and depth in
cardio-renal, immunology, neuroscience...
Selected assets, nearly all with exclusivity into 2030+
Cardio-Renal
3 INNOVATION
New for Q4
Immunology
Asset
LeqvioⓇ
Indication
Peak Sales
Next Milestone/ Status
Hyperlipidemia
Approved
CVRR-LDLC
Ph3 ORION-4 and VICTORION-2-
PREVENT ongoing
2026+
Iptacopan1
IgAN
Ph3 APPLAUSE-IgAN ongoing
20232
C3G
Ph3 APPEAR-C3G ongoing
2023
iMN
Ph2b ongoing
Pelacarsen
CVRR-Lp(a)
Ph3 Lp(a)HORIZON ongoing
2026+
2025
Ligelizumab
CSU
Submission
Asset
Indication
Peak Sales Next Milestone/ Status
Submission
CosentyxⓇ
HS
Ph3 SUNRISE, SUNSHINE
positive readout
2022
GCA
jPsA/ERA
Lupus Nephritis
Lichen Planus
Ph3 ongoing
2024
Aproved (US) in Q4
Ph3 SELUNE ongoing
2026+
Ph2b PRELUDE readout in 2022
2025
Ph3 PEARL 1, 2 readout
TBC
Food allergy3
CINDU
Ph3 ongoing
2025
Ph3 PEARL-PROVOKE ongoing
2025
Neuroscience
Remibrutinib¹
CSU
Ph3 REMIX-1 and -2 ongoing
2024
Asset
Indication
Peak Sales
Next Milestone/ Status
Submission
ZolgensmaⓇ
SMA IT
Ph3 STEER initiating
2025
lanalumab
Other indications being explored
Sjögren's
SLE
Ph3 start in 2022
2026+
Ph2a ongoing
2026+
Branaplam
Huntington's disease
Remibrutinib¹ Multiple sclerosis
Ph2b VIBRANT-HD ongoing
Ph3 REMODEL-1 and -2 ongoing 2025
2026+
Autoimmune hepatitis
Ph2b ongoing
2026+
Lupus Nephritis
Ph3 start in 2022
2026+
Iscalimab
DLX3134
Parkinson's disease
Ph2 ongoing
2026+
Unprobabilized peak sales (USD): <1bn .. 1-2bn
... >2bn
Liver Tx
Sjögren's
HS
Ph2b ongoing
2026+
Ph2b ongoing
2026+
Ph2a ongoing
2026+
'Wild Cards'
LNA043 (osteoarthritis: Ph2 ongoing), CSJ117 (asthma: Ph2b ongoing, COPD: Ph2 ongoing), QBW251 (COPD: Ph2b readout H1 2022), SAF312 (COSP: Ph2b ongoing), UNR844
(presbyopia: Ph2b readout H2 2022)
1. Peak sales potential based on all studied indications. 2. Based on 9 months UPCR readout (US accelerated approval). 3. Food Allergy indication falls within the Respiratory & Allergy therapeutic area 4. =UCB0599
17 Investor Relations | Q4 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation